Navigation Links
FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids

HealthDay Reporter

SATURDAY, July 12, 2014 (HealthDay News) -- There's no way to guarantee that a surgical technique used to grind up uterine growths and remove them through tiny incisions won't increase the risk of spreading cancer to other parts of a woman's body, U.S. health advisers said Friday.

The advisory panel to the Food and Drug Administration also said that women who do undergo the procedure -- called laparoscopic power morcellation -- should sign a written consent stating that they understand the potential risks, the Associated Press reported.

The panel's advisory opinion follows an April 17 warning from the FDA that the procedure can inadvertently spread cancerous tissue beyond a woman's uterus and into other parts of her body.

The FDA hasn't set a decision date on the use of power morcellator devices, the AP said. The agency isn't obliged to follow the advice or recommendations of its advisory committees but usually does so.

Surgeons frequently use laparoscopic power morcellation when they perform a hysterectomy or remove uterine fibroids, which are noncancerous growths on the smooth muscle tissue on the wall of the uterus.

The minimally invasive procedure uses a power tool to chop up the tissue of the fibroids or, in the case of a hysterectomy, the uterus itself. These tissue fragments are then removed through tiny incisions, according to background information from the FDA.

The agency estimates that about one in 350 women undergoing a hysterectomy or fibroid removal has an unsuspected type of cancer called uterine sarcoma.

If a surgeon performs power morcellation on these women, there's a risk the procedure will spread the cancerous tissue within the patient's abdomen and pelvis.

About 60,000 of these procedures are performed every year, estimated Dr. William Maisel, deputy director for science and chief scientist at the FDA's Center for Devices and Radiological Health.

The FDA stopped short in April of banning the power morcellation devices from the market, but is urging physicians and patients to weigh the risks prior to their use.

"Women should ask their health care provider if power morcellation will be used during the procedure, and explain why it's the best option," Maisel said at an April 17 news conference.

Women who already have undergone power morcellation don't need to get a cancer screening, because some of the tissue removed during the procedure would have been sent for pathologic analysis, Maisel said. If cancer had been detected, they would have been informed, he added.

"We think that most women who have undergone these procedures require routine care," he said. "If they don't have any ongoing or recurrent symptoms, they should be fine."

Most women will develop uterine fibroids at some point in their lives, according to the U.S. National Institutes of Health. These fibroids can cause symptoms such as heavy or prolonged menstrual bleeding, pelvic pain or frequent urination.

Women who need a hysterectomy or fibroid removal can still undergo traditional or laparoscopic surgery, just without the use of a power morcellator, Maisel said.

The agency has instructed manufacturers of power morcellators to review their current product labeling for accurate risk information for patients and health care professionals.

The FDA approved the first power morcellator for use in 1995, Maisel said. A non-power version of the morcellator received FDA approval in 1991.

The medical community has been aware of the risk of cancer spread during power morcellation since the devices came onto the market, Maisel said, but "the magnitude of the risk appears to be higher than what was appreciated in the clinical community."

More information

For more about uterine sarcoma, visit the U.S. National Cancer Institute.

SOURCES: April 17, 2014, U.S. Food and Drug Administration news briefing with William Maisel, M.D., M.P.H., deputy director for science and chief scientist, Center for Devices and Radiological Health; Associated Press

Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Back Pill to Help Prevent HIV Infection
2. U.S. Advisers Say No to Routine PSA Tests for Prostate Cancer
3. Tree nut consumption associated with lower body weight and lower prevalence of health risks
4. Even Preschoolers View the Overweight Negatively
5. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
6. Overweight Pregnant Women at Higher Risk for Complications
7. Can weight loss help African-American breast cancer survivors?
8. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
9. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
10. Research examines when benefits of screening mammography outweigh the harms for women in their 40s
11. Healthy Weight Loss May Also Cut Your Cancer Risk
Post Your Comments:
Related Image:
FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: